Patients Choice Laboratories of Indiana, LLC

Patients Choice Laboratories of Indiana, LLC was paid $23.42M by Medicaid between Jan 2018 and Dec 2024, across 148 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 39% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Indiana

Rank by total paid#2 of 66

Median peer was paid$53K

This provider vs. median445×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	24,396	$470K
2019	21,341	$1.62M
2020	58,696	$2.49M
2021	161,779	$4.81M
2022	223,056	$5.70M
2023	235,264	$5.63M
2024incomplete	167,697	$2.70M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	39%	126,399	69,331	$9.18M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	11%	40,740	31,764	$2.62M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	7.4%	42,421	21,580	$1.72M
87150		7.2%	32,684	25,844	$1.68M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	6.7%	61,938	33,946	$1.57M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	4.4%	49,604	19,882	$1.04M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	2.9%	15,889	10,384	$684K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	2.7%	29,615	13,970	$635K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	1.3%	11,592	9,975	$305K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.2%	38,462	13,548	$292K
87500		1.2%	31,858	25,360	$278K
87481		1.2%	26,040	20,479	$270K

136 more codes

87641		1.0%	32,315	$238K
87653		<1%	27,434	$216K
87640		<1%	34,577	$183K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	12,653	$153K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	12,654	$152K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	12,254	$144K
81381		<1%	1,308	$121K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	13,847	$111K
87486		<1%	11,046	$87K
87581		<1%	11,049	$87K
87496		<1%	10,827	$86K
87532		<1%	10,831	$86K
87541		<1%	10,326	$82K
87563		<1%	5,274	$78K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	4,542	$75K
87631		<1%	1,388	$74K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	7,651	$67K
87498		<1%	10,831	$66K
81418		<1%	1,022	$58K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	979	$56K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	1,060	$54K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	12,391	$48K
80074		<1%	2,349	$47K
81226		<1%	1,309	$44K
84443	Thyroid stimulating hormone (TSH)	<1%	9,104	$42K
81513		<1%	1,880	$37K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	650	$37K
80053	Comprehensive metabolic panel	<1%	12,295	$36K
80061	Lipid panel	<1%	7,703	$31K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	2,914	$29K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	13,627	$28K
82607		<1%	6,482	$28K
81401		<1%	1,337	$27K
87522	Neg quan hep c or qual rna	<1%	1,387	$24K
81225		<1%	1,309	$24K
83036	Hemoglobin; glycosylated (A1C)	<1%	7,869	$22K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	1,581	$20K
81240		<1%	895	$18K
81400		<1%	1,335	$17K
81335		<1%	1,184	$15K
81403		<1%	689	$15K
81227		<1%	1,310	$15K
84481		<1%	2,042	$14K
86481		<1%	271	$14K
84403		<1%	1,383	$13K
81241		<1%	892	$13K
86780		<1%	1,942	$12K
81231		<1%	1,325	$12K
81230		<1%	1,325	$12K
87529		<1%	612	$11K
82746		<1%	2,105	$11K
81256		<1%	891	$11K
84439		<1%	4,044	$10K
81328		<1%	909	$8K
81003		<1%	5,770	$7K
83735		<1%	2,928	$7K
81232		<1%	905	$6K
87505		<1%	259	$6K
81291		<1%	1,310	$5K
80050	General health panel	<1%	142	$5K
82728		<1%	1,111	$4K
80048	Basic metabolic panel (calcium, ionized)	<1%	2,325	$4K
83540		<1%	1,688	$4K
82670		<1%	667	$4K
81283		<1%	906	$4K
87340		<1%	1,128	$4K
86376		<1%	641	$4K
81247		<1%	910	$4K
87471		<1%	938	$4K
84153		<1%	647	$3K
83550		<1%	1,116	$3K
86703		<1%	441	$3K
81355		<1%	906	$3K
83003		<1%	278	$3K
84144		<1%	510	$3K
82627		<1%	353	$2K
83001		<1%	501	$2K
84270		<1%	378	$2K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	246	$2K
86803		<1%	632	$2K
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	<1%	1,947	$2K
83970		<1%	193	$2K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	374	$2K
82533		<1%	289	$2K
83002		<1%	297	$1K
36415	Collection of venous blood by venipuncture	<1%	929	$1K
82570		<1%	634	$994.37
83525		<1%	284	$991.39
87625		<1%	37	$835.34
80164		<1%	322	$810.23
84480		<1%	361	$692.38
85651		<1%	517	$690.44
83090		<1%	126	$670.66
81402		<1%	647	$651.65
82977		<1%	306	$646.36
87086	Culture, bacterial; quantitative colony count, urine	<1%	230	$570.68
86140		<1%	523	$557.53
80076		<1%	1,464	$557.14
81001		<1%	618	$544.46
83880		<1%	89	$504.39
82550		<1%	259	$476.63
84436		<1%	1,162	$426.85
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	22	$406.87
86431		<1%	204	$388.27
85610		<1%	383	$318.50
84681		<1%	46	$303.73
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	1,459	$285.80
84402		<1%	12	$243.23
82140		<1%	97	$239.08
83615		<1%	103	$230.96
82626		<1%	14	$225.57
87186		<1%	74	$196.96
84146		<1%	14	$196.43
87088		<1%	77	$184.21
84156		<1%	166	$178.84
85027		<1%	120	$146.84
82040		<1%	291	$146.37
80364		<1%	78	$137.61
80365		<1%	64	$135.59
84550		<1%	261	$113.81
80346		<1%	59	$109.12
86706		<1%	29	$107.83
83721		<1%	163	$78.12
83690		<1%	63	$70.51
81025		<1%	29	$49.63
82150		<1%	52	$45.02
85045		<1%	15	$35.30
85652		<1%	29	$21.18
85018		<1%	18	$13.47
84100		<1%	16	$9.81
85007		<1%	109	$4.56
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	0%	152	$0.00
80354		0%	101	$0.00
81479	Unlisted molecular pathology procedure	0%	18	$0.00
80358		0%	155	$0.00
G0433	Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening	0%	41	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMOSS, BRADLEY (CEO)